This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Guelph directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $280,788
Clinical Advancement of an AAV Lung Gene Therapy Platform for the Treatment of Monogenic Lung Diseases
CIHR · 2019 · Principal investigator
Clinical Advancement of an AAV Lung Gene Therapy Platform for the Treatment of Monogenic Lung Diseases
Principal investigators: Wootton, Sarah; Thompson, Brad; Thebaud, Bernard
Keywords: Abca3 Deficiency; Adeno-Associated Virus Vector; Alveolar Type Ii Cells; Cystic Fibrosis; Gene Editing; Gene Replacement; Monogenic Lung Diseases; Surfactant Protein B Deficiency; Surfactant Protein C; Toxic Gain Of Function
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.